Document is current
Any future updates will be listed below
-
Authors
Gambacorti-Passerini, Carlo https://orcid.org/0000-0001-6058-515X
Brümmendorf, Tim H. https://orcid.org/0000-0002-9677-3723
Abruzzese, Elisabetta https://orcid.org/0000-0001-5228-6491
Kelly, Kevin R.
Oehler, Vivian G.
García-Gutiérrez, Valentín https://orcid.org/0000-0003-4752-0815
Hjorth-Hansen, Henrik https://orcid.org/0000-0002-2670-5696
Ernst, Thomas https://orcid.org/0000-0003-2147-489X
Leip, Eric
Purcell, Simon
Luscan, Gerald
Viqueira, Andrea
Giles, Francis J.
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 14 February 2024
Revised: 8 July 2024
Accepted: 1 August 2024
First Online: 20 August 2024
Competing interests
: CG-P: consultancy (Bristol Myers Squibb), honoraria and research funding (Pfizer). THB: research funding (Bristol Myers Squibb, Novartis, Pfizer, Repeat Diagnostic); honoraria (Janssen, Novartis, Pfizer, Takepart Media); consultancy (Pfizer). EA: consultancy and honoraria (Bristol Myers Squibb, Incyte, Novartis, Pfizer). KRK: consultancy (Amgen, AstraZeneca, Denovo Biopharma, Sanofi-Aventis, Takeda, Verastem); equity holder (Agios, Berkley Lights); Speakers Bureau (Bayer, Celgene, Epizyme, Gilead, Janssen, Karyopharm, Novartis, Pharmacyclics). VGO: research funding and lectures (Pfizer); consultancy (Pfizer, Novartis, Ascentage, Terns); honoraria (OncLive). VG-G: research funding (Pfizer, Novartis, BMS, Incyte); consultancy (Bristol Myers Squibb, Incyte, Novartis). HH-H: research funding and lectures (AOP, Incyte, Pfizer).TE: research support from Bristol Myers Squibb, Incyte, Novartis, and Pfizer. EL, SP, GL, AV: employee (Pfizer); equity holder (Pfizer). FJG: consultancy (Novartis). AH: research funding (Bristol Myers Squibb, Incyte, Novartis, Pfizer).
: This research is in accordance with the Declaration of Helsinki. This study did not use a central ethics committee, rather, separate ethics committees at each study site reviewed and approved the protocol. Informed consent was obtained from all participants before study procedures began.
